New hope for brain-spread cancers: dual immunotherapy injected into spinal fluid
NCT ID NCT05598853
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This early-phase study tests a new way to give immunotherapy drugs (nivolumab and ipilimumab) to people with lung cancer or melanoma that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The drugs are given both into the spinal fluid and through a vein. The main goal is to find the safest dose and see if this approach can control the cancer. About 26 adults with newly diagnosed leptomeningeal metastases will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Basel
Basel, Switzerland
-
University Hospital Geneva
Geneva, Switzerland
-
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Conditions
Explore the condition pages connected to this study.